HIGHLIGHTS
- who: Manman Xu and colleagues from the Department of Obstetrics and Gynecology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China have published the paper: Platinum-Resistant Ovarian Cancer Is Vulnerable to the cJUN-XRCC4 Pathway Inhibition, in the Journal: Cancers 2022, 14, 6068. of /2022/
- what: The authors have shown that cJUN acted as the transcription factor of XRCC4 in the A2780cisR and SKOV3cisR treated with cisplatin. The authors demonstrated that XRCC4-mediated NHEJ DNA damage repair also contributes to cisplatin resistance in ovarian cancer. Interestingly, the study also revealed that the expression . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.